Hypersensitivity to the active substance or to any of the excipients listed in Description.
For patients with NSCLC, ramucirumab is contraindicated where there is tumour cavitation or tumour involvement of major vessels (see Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education